FcRn blockers appear to be a promising first FDA-approved treatment option for Sjögren's disease. According to early data, they are proving to be effective. In Sjögren's disease, B-cell activation leads to the production of immunoglobulins. Johnson & Johnson has been testing the antibody nipocalimab, acquired in the $6.5 billion acquisition of Momenta. In a phase 2 study, nipocalimab met its primary endpoints. The treatment could be the first approved option for the disease.